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in blood pressure and mean arterial pressure 
reduction in ambulatory blood pressure 
monitoring with remogliflozin etabonate 
200 mg coprescribed with recent onset  
anti-hypertensive drugs
ABSTRACT
Introduction. Hypertension is commonly occurring in 
type 2 diabetes and metabolic syndrome and inflam-
mation are a well-known part of this disease entity. 
The data of using remogliflozin in Indian patient is 
not known as this is a very recently approved mol-
ecule for the treatment of type 2 diabetes. Here we 
look into a case series of five patients who had their 
ambulatory blood pressure monitoring (ABPM) done at 
baseline and again after 14 days of therapy of adding 
remogliflozin etabonate to recent onset antihyper-
tensive druges. 
Methods. We analysed the ABPM results of five patients 
after taking their informed consent at baseline and 
two weeks post-treatment initiation with remogliflozin 
alongside with recent onset antihypertensive drugs. 
We used paired t test for statistical analysis of the 
two readings of each patient to come to a conclusion. 
Results. We found a statistically significant decrease in 
mean arterial pressure (MAP) reflected by a p value of 
0.0277 and the reduction in mean awake time systolic 
blood pressure (SBP) was also very close to statistical 
significance as seen by the p value of 0.0541. 
Conclusions. Remogliflozin etabonate when co-pre-
scribed with antihypertensive drugs shows a significant 
reduction in MAP as well as reduction in SBP although 
most of the contribution seems to be coming from the 
antihypertensive molecule itself. (Clin Diabetol 2019; 
8, 5: 254–257)
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Introduction
Hypertension is a common entity among diabetic 
patients, with the prevalence determined by type as 
well as the duration of diabetes with the other con-
tributing factors being race/ethnicity, sex, age, BMI, 
presence of kidney disease and glycemic control [1]. 
A large subset of participants (60%) in the Avoiding 
Cardiovascular Events Through Combination Therapy 
in Patients Living With Systolic Hypertension (ACCOM-
PLISH) trial were at high risk of cardiovascular events 
and benazepril plus the dihydropyridine calcium chan-
nel blocker amlodipine showed a decrease in morbidity 
and mortality when compared with the benazepril plus 
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the thiazide-like diuretic hydrochlorothiazide [2, 3]. There 
is a decrease in blood pressure of ~1 mm Hg with the loss 
in body weight by 1 kg [4]. In recent times SGLT2Is are 
widely used to control glycemia along-with many other 
parameters as they have shown multiple benefits includ-
ing reduction in nephropathy and hypertension. Amongst 
the SGLT2Is marketed presently in India, remogliflozin is 
the newest one to get approval for diabetes control in 
type 2 diabetes. The data of remogliflozin in blood pres-
sure reduction is sparse as the molecule is in its nascent 
state. Dobbins et al. in their study have shown that ad-
ministration of remogliflozin etabonate for 12 days leads 
to clinically significant improvements in plasma glucose 
as well as changes in body weight and blood pressure 
in type 2 diabetic patients [5]. This case series is the first 
of its kind from India demonstrating the marked reduc-
tion in SBP, DBP and MAP when remgoliflozin etabonate 
200 mg is co-prescribed with anti-hypertensive druges. 
Case series presentation
There were five type 2 diabetic patients (after 
taking proper written informed consent) who had a 
baseline ambulatory blood pressure monitoring (ABPM) 
report as well as ABPM report done after two weeks 
available. All of the patients were put on antihyperten-
sive drugs three days prior to recording the baseline 
ABPM to see the dipping status of each patient and 
again the ABPM machine was re-installed after fourteen 
days of initiating remogliflozin 200 mg to see the final 
outcome of antihypertensive therapy and diurnal varia - 
tion after drug initiation. Baseline characters of the 
patients and the drugs used are depicted in Table 1 who 
were all put on remogliflzoin 200 mg per day (BID).
Methods
Informed consent was taken from all the partici-
pants. All protocols were followed as per declaration 
laid down in the Declaration of Helsinki. 
Statistical analysis
We analysed the clinic data record of the author 
of five selected type 2 diabetic patients with hyperten-
sion who were recently put on antihypertensive drugs 
and three days after starting it, each one was put 
on remogliflozin etabonate 200 mg. We used paired 
t test for comparison between the baseline and post-
treatment values of ABPM for each individual. We took 
a p value of < 0.05 as statistically significant.
Results
This case series showed a reduction in SBP, DBP and 
a statistically significant drop in MAP after computing 
the results in paired t-test (Table 2). The p-value of mean 
changes in SBP during day time was 0.0541, p-value of 
mean changes in SBP during night time was 0.7828, 
p-value of mean changes in DBP during day time was 
0.0607, p-value of mean changes in DBP during sleep 
time was 0.1533 and the change in p-value in MAP 
was 0.0277 which was statistically significant. The 
mean awake SBP showed a marked reduction with the 
p-value close to statistical significance (p = 0.0541). An 
interesting finding of this ABPM was a change in the 
dipping status (Table 3) which was present in both the 
systolic and diastolic arms at baseline but there was 
not much change after treatment in the diastolic arm 
while it actually increased in the systolic arm making it 
a reverse dipping once the average is seen. The reason 
Table 1. Baseline characters and drugs used in the case series analysis 
Serial  
Number
Age Sex Duration  
of hypertension
Anti-diabetic  
drugs
Duration  
of diabetes
Anti-hypertensive 
drugs
BMI  
[kg/m2]
HbA1c  
(%)
1 62 years M 3 years 4.5 months Metformin 1000 mg; 
glimepiride 1 mg
Olmesartan 20;  
chlorthalidone 12.5 mg
25.7 7.8
2 63 years M 4.5 years 4 months Metformin 1500 mg; 
glimepiride 2 mg
Telmisartan 40;  
chlorthalidone 12.5 mg
26.9 7.7
3 60 years M 4 years 2 months Metformin 2000 mg; 
glimepiride 2 mg
Amlodipine 5;  
chlorthalidone 12.5 mg
27 8.1
4 65 years M 5 years 2 months Metformin 2000 mg; 
teneligliptin 20 mg; 
glimepiride 1 mg
Chlorthalidone 12.5 mg 28.8 7.3
5 60 years F 2 years 3 months Metformin 1500 mg; 
glimepiride 2 mg 
Amlodipine 5;  
chlorthalidone 12.5 mg
25.3 7.4
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to it seems to come from the reading of a single patient 
who had a very substantial increase in his SBP and DBP 
readings that surpassed the reduction property seen 
with the others but the reason of this increase is not 
known (could have been any severe stress or compli-
ance issue). 
Discussion
In lower-income and developing countries we are 
getting an epidemic in the prevalence of obesity and 
type 2 diabetes (T2D) attributed to changed lifestyles 
with high caloric intake and low energy expenditure 
[6]. India has the highest prevalence of diabetes in the 
world mostly because of the above mentioned reasons 
and cheap medicines of the class of SGLT2Is are in huge 
demand to tackle this epidemic in India as they have 
multi modalities of action due to their class effect. The 
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor and 
Angiotensin Receptor Blocker (ARB) Combination Thera-
py in Patients with Diabetes and Uncontrolled Nocturnal 
Hypertension study (SACRA) was done to investigate 
changes in blood pressure with existing antihypertensive 
therapy and empagliflozin and it showed older diabetes 
patients who are nonseverely obese having uncontrolled 
hypertension at night-time had a significant blood pres-
sure reduction without significant reductions in glyce-
mic parameter [7]. In an animal study by Nakano et al. 
it was seen that out of canagliflozin, dapagliflozin and 
remogliflozin, only remogliflozin showed a reduction 
in oxygen radical absorbance capacity (ORAC) as well 
as there was marked lowering of both serum alanine 
aminotransferase (76%) and aspartate aminotransferase 
(48%), and there was also reduction in hepatic trigly-
ceride content by 40% and liver weight by 42% [8]. The 
use of approved SGLT2 inhibitors was associated with 
mean reduction of systolic and diastolic blood pressure 
of 4.0 mm Hg and 1.6 mm Hg, respectively, compared 
with baseline [9]. This case series is the first data from 
Indian patients who were co-prescribed remogliflozin 
and antihypertensive drugs with chlorthalidone being 
present in all the groups showing improvements in 
mean SBP and mean DBP and a statistically significant 
reduction in MAP. There were few limitations of this case 
series analysis: small sample size makes it impossible 
to conclude that remogliflozin has potent BP reducing 
capacity as there was concomitant administration of 
antihypertensives; there was no chance to intervene in 
the lifestyle of the patients to find out the modifications 
they are applying themselves to correct their hyperten-
sion other than those prescribed by the author; they also 
did not tell the author about any illness which might 
have happened during the time of ABPM recording.
Table 3. Dipping property at baseline and after follow-up
Mean  
awake  
SBP (B/L) 
Avg
Mean 
sleep  
SBP (B/L) 
Avg
Mean 
awake  
SBP (F/UP) 
Avg
Mean 
sleep SBP 
(F/UP) 
Avg
Mean 
awake 
DBP (B/L) 
Avg
Mean 
sleep DBP 
(B/L) 
Avg
Mean  
awake DBP 
(F/UP) 
Avg
Mean 
sleep DBP 
(F/UP) 
Avg
%  
change  
of SBP 
%  
change  
of DBP 
Dipping 
status  
B/L
Dipping 
status  
F/UP
129 123.8 122.2 125.2 79 72.6 66.4 65.4 B/L: 4.03  
F/UP: 
–2.45
B/L: 8.1 
F/UP:  
1.5
Present Reduced 
but  
present 
for DBP 
but lost  
in SBP
Avg — average; B/L — baseline; DBP — diastolic blood pressure; SBP — systolic blood pressure; F/UP — follow-up
Table 2. Paired t test analysis of baseline and follow-up values of different parameters of ABPM 
Baseline Follow-Up Absolute change 
from baseline
95% CI P value
Mean awake time SBP [mm Hg] 129 ± 8.09 122 ± 6.98 –6.8 –13.79 to 0.19 0.0541 
Mean awake time DBP [mm Hg] 79 ± 6.78 66.4 ± 6.84 –12.6 –26.11 to 0.91 0.0607
Mean sleep time SBP [mm Hg] 123.8 ± 14.77 125.2 ± 23.66 1.4 –11.79 to 14.59 0.7828 
Mean sleep time DBP [mm Hg] 72.6 ± 10.83 65.4 ± 10.92 –7.2 –18.56 to 4.16 0.1533
MAP [mm Hg] 94 ± 8.37 85.4 ± 6.11 –8.6 –15.66 to –1.54 0.0277*
*Signifies statistically significant; DAB — diastolic blood pressure; SBP — systolic blood pressure; MAP — mean arterial pressure; CI — confidence interval
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Conclusions
Our case series analysis shows for the first time the 
possibility of significant SBP and DBP reduction with 
remogliflozin and antihypertensives but we need large 
randomised trials or larger real-world data to have a 
final conclusion. Till that time we can presume that 
remogliflozin also shares the same pleotropic benefit of 
BP reductions to some extent like shown by the existing 
three SGLT2Is. The significant BP reduction shown here 
may be a chance finding as in real-world setting the BP 
reductions seen with SGLT2I is much lesser than seen 
in this case series and hence it is mostly contributed by 
the antihypertensive therapy that was given. 
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